DOCSLIB.ORG

Pancreatic Cancer Drugs in the Pipeline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pancreatic Cancer Drugs in the Pipeline HemOnc today | APRIL 25, 2016 | Healio.com/HemOnc 57 Pancreatic Cancer Drugs in the Pipeline HEMONC TODAY presents this guide to drugs in phase 2 or phase 3 development for pancreatic cancer. Clinicians can use this chart as a quick reference to learn about the status of those drugs that may be clinically significant to their practice. Generic name (Brand name, Manufacturer) Indication(s) Development status ABT-888 (Abbott) combination treatment for metastatic disease phase 2 ACP-196 (Acerta Pharma) combination therapy for advanced or metastatic disease phase 2 aglatimagene besadenovec (Advantagene) nonmetastatic disease phase 2 algenpantucel-L (NewLink Genetics) borderline resectable or locally advanced unresectable disease; surgically phase 3 resected disease ALT-803 (Altor Bioscience Corporation) combination treatment for advanced disease phase 2 apatorsen (OncoGenex Pharmaceuticals) treatment-naive metastatic disease phase 2 BAX2398 (Baxalta) combination treatment phase 2 BC-819 (BioCancell Therapeutics) first-line treatment phase 2 BPM 31510 (Berg LLC) advanced disease phase 2 cabozantinib (Cometriq, Exelixis) advanced pancreatic neuroendocrine and carcinoid tumors phase 2 cancer macrobeads (Metromedia Bio-Science and Rogosin Institute) treatment-resistant disease phase 2 CPI-613 (Cornerstone Pharmaceuticals) combination treatment phase 2 CRS-207 (Aduro Biotech) combination treatment phase 2 dacomitinib (Pfizer) combination treatment for advanced KRAS-mutant disease phase 2 demcizumab (OncoMed Pharmaceuticals) combination first-line treatment for metastatic disease phase 2 ensituximab (NPC-1C, Precision Biologics) metastatic disease phase 2 evofosfamide (TH-302, EMD Serono and Threshold Pharmaceuticals) combination treatment for metastatic or locally advanced, unresectable disease phase 3 FG-3019 (Fibrogen) combination treatment for locally advanced, unresectable disease phase 2 galunisertib (Eli Lilly) pancreatic cancer phase 2 GI-4000 (GlobeImmune) resected disease phase 2 glufosfamide (Eleison Pharmaceuticals) second-line treatment for metastatic disease phase 3 GSK2256098 (GlaxoSmithKline) combination treatment for advanced disease phase 2 GVAX Pancreas (Aduro Biotech) surgically resectable disease phase 2 ibrutinib (Imbruvica, Janssen and Pharmacyclics) advanced carcinoid and pancreatic neuroendocrine tumors phase 2 INCB039110 (Incyte) combination treatment for advanced disease phase 2 ipilimumab (Yervoy, Bristol-Myers Squibb) combination treatment for metastatic disease phase 2 Kanglaite injection (KangLaiTe USA) pancreatic cancer phase 2 masitinib (AB Science USA) combination treatment for advanced or metastatic disease phase 3 MM-141 (Merrimack Pharmaceuticals) combination treatment for frontline metastatic disease phase 2 MM-398 (Onivyde, Baxalta and Merrimack Pharmaceuticals) first-line treatment phase 2 momelotinib (Gilead Sciences) combination treatment for treatment-naive, metastatic disease phase 3 necuparanib (M402, Momenta Pharmaceuticals) combination treatment for metastatic disease phase 2 nimotuzumab (Biotech Pharma) combination treatment for KRAS wild-type locally advanced or metastatic disease phase 2 NPC-1C (Precision Biologics) combination treatment phase 2 olaparib (Lynparza, AstraZeneca) BRCA–positive disease; metastatic disease phase 2 BRCA–mutated disease that has not progressed on first-line platinum-based phase 3 chemotherapy oregovomab (Quest PharmaTech) combination treatment for locally advanced disease phase 2 paclitaxel protein-bound particles for injectable suspension adjuvant therapy phase 3 [albumin-bound] (Abraxane, Celgene) pazopanib (Votrient, Novartis) advanced pancreatic neuroendocrine tumors phase 2 PBI-05024 (Phoenix Biotechnology) stage IV metastatic disease phase 2 PEGPH20 (Halozyme Therapeutics) combination treatment for stage IV untreated disease; combination phase 2 treatment for newly diagnosed metastatic disease pelareorep (Reolysin, Oncolytics Biotech) combination treatment for advanced or metastatic disease phase 2 pembrolizumab (Keytruda, Merck) resectable or borderline resectable disease phase 2 polyclonal antibody stimulator (G17DT, Cancer Advances Inc.) metastatic disease phase 3 regorafenib (Stivarga, Bayer) advanced disease phase 2 rucaparib (Clovis Oncology) pancreatic cancer with known deleterious BRCA mutation phase 2 ruxolitinib (Jakafi, Incyte) combination treatment for advanced or metastatic disease phase 3 SGT-53 (SynerGene Therapeutics) combination treatment for metastatic disease phase 2 sulfatinib (Hutchison Medipharma) advanced pancreatic neuroendocrine tumors phase 3 tarextumab (OncoMed Pharmaceuticals) combination treatment for previously untreated stage IV disease phase 2 TL-118 (Tiltan Pharma) pancreatic cancer previously treated with gemcitabine phase 2 trametinib (Mekinist, Novartis) combination treatment for advanced disease phase 2 X-82 (Tyrogenex) pancreatic neuroendocrine tumors phase 2 Information in this chart was compiled from the Pharmaceutical Research and Manufacturers of America, NIH (www.clinicaltrials.gov), corporate websites and the databases of HEMONC TODAY. The publisher or editors do not assume responsibility for any errors or omissions..
Load more

Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • PD-1 / PD-L1 Combination Therapies
    PD-1 / PD-L1 Combination Therapies Jacob Plieth & Edwin Elmhirst – May 2017 Foreword Sprinkling the immuno-oncology dust When in November 2015 EP Vantage published its first immuno- oncology analysis we identified 215 studies of anti-PD-1/PD-L1 projects combined with other approaches, and called this an important industry theme. It is a measure of how central combos have become that today, barely 18 months on, that total has been blown out of the water. No fewer than 765 studies involving combinations of PD-1 or PD-L1 assets are now listed on the Clinicaltrials.gov registry. This dazzling array owes much to the transformational nature of the data seen with the first wave of anti-PD-1/PD-L1 MAbs. It also indicates how central combinations will be in extending immuno-oncology beyond just a handful of cancers, and beyond certain patient subgroups. But the combo effort is as much about extending the reach of currently available drugs like Keytruda, Opdivo and Tecentriq as it is about making novel approaches viable by combining them with PD-1/PD-L1. On a standalone basis several of the industry’s novel oncology projects have underwhelmed. As data are generated it will therefore be vital for investors to tease out the effect of combinations beyond that of monotherapy, and it is doubtful whether the sprinkling of magic immuno-oncology dust will come to the rescue of substandard products. This is not stopping many companies, as the hundreds of combination studies identified here show. This report aims to quantify how many trials are ongoing with which assets and in which cancer indications, as well as suggesting reasons why some of the most popular approaches are being pursued.
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group)
    National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group) Working Group Report March 6, 2019 The report was accepted at the March 6, 2019 CTAC Meeting ______________________________________________________________________________________________________ PDAC Progress WG Report: Accepted by the Clinical Trials and Translational Research Advisory Committee on March 6, 2019 Page 1 TABLE OF CONTENTS Page National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 3 Working Group (PDAC Progress Working Group) Report Appendix 1: Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 16 Working Group (PDAC Progress WG) 2018 Roster Appendix 2: Funded Project Summary FY 2015 – FY 2017 • NIH PDAC Funded Projects, Initiative 1: Understanding the 18 Biological Relationship Between PDAC and Diabetes Mellitus • NIH PDAC Funded Projects, Initiative 2: Evaluating Longitudinal Screening Protocols, for Biomarkers for Earl Detection of PDAC 20 and its Precursors • NIH PDAC Funded Projects, Initiative 3: Study New Therapeutic 28 Strategies in Immunotherapy • NIH PDAC Funded Projects, Initiative 4: Developing New Treatment Approaches that Interfere with RAS Oncogene- 33 Dependent Signaling Pathways • NIH PDAC Funded Projects, No Related to the Framework t 38 Initiatives Appendix 3: PDAC Publications Supported by Grants
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Review Article Monoclonal Antibodies in Gynecological Cancer: a Critical Point of View
    Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2011, Article ID 890758, 16 pages doi:10.1155/2011/890758 Review Article Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View Filippo Bellati,1, 2 Chiara Napoletano,2 Maria Luisa Gasparri,1 Valeria Visconti,2 Ilaria Grazia Zizzari,2 Ilary Ruscito,1 Jlenia Caccetta,1 Aurelia Rughetti,2 Pierluigi Benedetti-Panici,1 and Marianna Nuti2 1 Department of Gynecology and Obstetrics, “Sapienza” University of Rome, Italy 2 Department of Experimental Medicine, “Sapienza” University of Rome, Italy Correspondence should be addressed to Marianna Nuti, [email protected] Received 2 July 2011; Revised 4 October 2011; Accepted 3 November 2011 Academic Editor: Enrico Maggi Copyright © 2011 Filippo Bellati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. During the last decades, several improvements in treating gynecological malignancies have been achieved. In particular, target therapies, mostly monoclonal antibodies, have emerged as an attractive option for the treatment of these malignancies. In fact, various molecular-targeted agents have been developed for a variety of malignancies with the objective to interfere with a precise tumor associated receptor, essential for cancer cell survival or proliferation, blocking its function, of the cancer cells. Alternatively, monoclonal antibodies have been developed to block immune suppression or enhance functions of immune effector cells. So far, several monoclonal antibodies have been tested for clinical efficacy for the treatment of gynecological cancers. Antibodies against Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) have been used in different neoplasms such as ovarian and cervical cancer.
    [Show full text]
  • The Emerging Role of CD24 in Cancer Theranostics—A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond
    Journal of Personalized Medicine Review The Emerging Role of CD24 in Cancer Theranostics—A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond Katrin Kleinmanns 1,* , Vibeke Fosse 1, Line Bjørge 1,2 and Emmet McCormack 1,3,4 1 Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway; [email protected] (V.F.); [email protected] (L.B.); [email protected] (E.M.) 2 Department of Obstetrics and Gyneacology, Haukeland University Hospital, 5021 Bergen, Norway 3 Centre for Pharmacy, Department of Clinical Science, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway 4 Department of Clinical Science, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway * Correspondence: [email protected] Received: 10 November 2020; Accepted: 26 November 2020; Published: 27 November 2020 Abstract: Complete cytoreductive surgery is the cornerstone of the treatment of epithelial ovarian cancer (EOC). The application of fluorescence image-guided surgery (FIGS) allows for the increased intraoperative visualization and delineation of malignant lesions by using fluorescently labeled targeting biomarkers, thereby improving intraoperative guidance. CD24, a small glycophosphatidylinositol-anchored cell surface receptor, is overexpressed in approximately 70% of solid cancers, and has been proposed as a prognostic and therapeutic tumor-specific biomarker for EOC. Recently, preclinical studies have demonstrated the benefit of CD24-targeted contrast agents for non-invasive fluorescence imaging, as well as improved tumor resection by employing CD24-targeted FIGS in orthotopic patient-derived xenograft models of EOC. The successful detection of miniscule metastases denotes CD24 as a promising biomarker for the application of fluorescence-guided surgery in EOC patients.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • PANI: a Novel Algorithm for Fast Discovery of Putative Target Nodes in Signaling Networks
    PANI: A Novel Algorithm for Fast Discovery of Putative Target Nodes in Signaling Networks Huey-Eng Chua§ Sourav S Bhowmick§ Lisa Tucker-Kellogg‡ Qing Zhao§ C F Dewey, Jr† Hanry Yu¶ §School of Computer Engineering, Nanyang Technological University, Singapore ‡Mechanobiology Institute, National University of Singapore, Singapore ¶Department of Physiology, National University of Singapore, Singapore †Division of Biological Engineering, Massachusetts Institute of Technology, USA chua0530|assourav|[email protected], LisaTK|[email protected], [email protected] ABSTRACT of disease [26]. Observation-based approaches screen drug Biological network analysis often aims at the target identifi- compounds in vitro, ex vivo, or in vivo; and measure em- cation problem, which is to predict which molecule to inhibit pirical outcome for determining which drugs are “active” (or activate) for a disease treatment to achieve optimum ef- against the disease. In contrast, target-based approaches ficacy and safety. A related goal, arising from the increasing identify a particular molecule (e.g., enzyme, receptor) that availability of semi-automated assays and moderately par- functions prominently in a validated mechanism of the dis- allel experiments, is to suggest many molecules as potential ease, and then synthesize a drug compound to interact specif- targets. The target prioritization problem is to predict a sub- ically with that target molecule. One key expectation in set of molecules in a given disease-associated network which target-based drug development is that specificity for one contains successful drug targets with highest probability. disease-causing molecule and lack of binding to other Sensitivity analysis prioritizes targets in a dynamic network molecules will minimize toxicity.
    [Show full text]
  • Targeted Molecular Therapies for Ovarian Cancer: an Update and Future Perspectives (Review)
    ONCOLOGY REPORTS 28: 395-408, 2012 Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review) HIROSHI SHIGETOMI, YUMI HIGASHIURA, HIROTAKA KAJIHARA and HIROSHI KOBAYASHI Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8522, Japan Received February 20, 2012; Accepted May 3, 2012 DOI: 10.3892/or.2012.1833 Abstract. Identification of the potential gene expression profiles Advances in surgical and chemotherapeutic management of epithelial ovarian cancer and the arrival of newly targeted have improved progression-free survival (PFS) and overall therapies have advanced the strategies used for treatment of survival (OS) over the past decade. Paclitaxel plus carboplatin this disease. This review focuses on the design of ongoing and combination is the primary treatment strategy in the front- planned clinical trials and offers a synopsis of the English- line setting. Unfortunately, many women eventually relapse language literature for preclinical and clinical targeted therapies after adjuvant therapy, and are at great risk of recurrence. A for epithelial ovarian cancer. Among many targeted agents, a major challenge is to understand the molecular mechanism promising, novel class of targeted drugs for special patient leading to the state of resistance to standard chemotherapy. populations expected to improve the effectiveness of current Novel drugs are being developed to target specific molec- therapy include inhibitors of angiogenesis, poly (ADP ribose) ular pathways (1). Knowledge of the pathogenesis of ovarian polymerase (PARP) and DNA repair mechanisms. Inhibition cancer has led to a better understanding and identification of PARP or homologous recombination (HR) repair mediated of potential molecular targets which hold great promise for by Chk1 (checkpoint kinase 1) would selectively sensitize p53 personalized treatment.
    [Show full text]